TA-058の臨床的検討

梅枝 愛郎; 福山 展; 金井 君江; 片貝 重之; 秋谷 寿一; 松尾 英徳; 稲沢 正士; 中沢 次夫; 笛木 隆三; 小林 節雄; 関 健鑑

doi:10.11250/chemotherapy1953.32.Supplement2_222

CLINICAL STUDY OF TA-058

YOSHIO UMEGAE, HIROSHI FUKUYAMA, KIMIE KANAI, SHIGEYUKI KATAKAI, JUICHI AKIYA, HIDENORI MATSUO, MASAHITO INAZAWA, TSUGIO NAKAZAWA, RYUZO FUEKI, SETSUO KOBAYASHI, KENKAN KAN

Author information

YOSHIO UMEGAE
Department of Internal Medicine, Maebashi Red Cross Hospital
HIROSHI FUKUYAMA
Department of Internal Medicine, Maebashi Red Cross Hospital
KIMIE KANAI
Department of Internal Medicine, Maebashi Red Cross Hospital
SHIGEYUKI KATAKAI
Department of Internal Medicine, Maebashi Red Cross Hospital
JUICHI AKIYA
Department of Internal Medicine, Maebashi Kyoritsu Hospital
HIDENORI MATSUO
Department of Internal Medicine, Maebashi Kyoritsu Hospital
MASAHITO INAZAWA
First Department of Internal Medicine, School of Medicine, Gunma University
TSUGIO NAKAZAWA
First Department of Internal Medicine, School of Medicine, Gunma University
RYUZO FUEKI
First Department of Internal Medicine, School of Medicine, Gunma University
SETSUO KOBAYASHI
First Department of Internal Medicine, School of Medicine, Gunma University
KENKAN KAN
Department of Internal Medicine, Toho Hospital

JOURNAL FREE ACCESS

1984 Volume 32 Issue Supplement2 Pages 222-224

DOI https://doi.org/10.11250/chemotherapy1953.32.Supplement2_222

Details

Abstract

TA-058 has been studied clinically, and the following results were obtained.
1. TA-058 was administered to 10 patients; 9 respiratory tract infections, and 1 urinary tract infection.
2. TA-058 was given intravenously at a daily dose of 1 to 4 g to these patients.
3. Clinical response was excellent in 3 patients, effective in 5 and fair in 2.
3. Clinical response was excellent in 3 patients, effective in 5 and fair in 2.
4. Laboratory examinations revealed eosinophilia in 1 patient. No side effects were observed.

Corresponding author

Register with J-STAGE for free!